nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—SRC—colon cancer	0.207	0.405	CbGaD
Vandetanib—VEGFA—colon cancer	0.165	0.323	CbGaD
Vandetanib—EGFR—colon cancer	0.139	0.272	CbGaD
Vandetanib—ABCC1—Irinotecan—colon cancer	0.0314	0.165	CbGbCtD
Vandetanib—ABCC1—Vincristine—colon cancer	0.0275	0.144	CbGbCtD
Vandetanib—ABCG2—Irinotecan—colon cancer	0.021	0.11	CbGbCtD
Vandetanib—ABCG2—Fluorouracil—colon cancer	0.0202	0.106	CbGbCtD
Vandetanib—ABCG2—Vincristine—colon cancer	0.0184	0.0963	CbGbCtD
Vandetanib—ABCC1—Methotrexate—colon cancer	0.0166	0.0871	CbGbCtD
Vandetanib—ALB—Irinotecan—colon cancer	0.0145	0.076	CbGbCtD
Vandetanib—ALB—Fluorouracil—colon cancer	0.0139	0.0729	CbGbCtD
Vandetanib—ABCG2—Methotrexate—colon cancer	0.0111	0.0583	CbGbCtD
Vandetanib—ALB—Methotrexate—colon cancer	0.00767	0.0402	CbGbCtD
Vandetanib—CYP3A4—Irinotecan—colon cancer	0.00454	0.0238	CbGbCtD
Vandetanib—CYP3A4—Vincristine—colon cancer	0.00397	0.0208	CbGbCtD
Vandetanib—ORM1—bile—colon cancer	0.0021	0.0262	CbGeAlD
Vandetanib—KDR—umbilical vein—colon cancer	0.00174	0.0217	CbGeAlD
Vandetanib—FLT4—endothelium—colon cancer	0.00126	0.0157	CbGeAlD
Vandetanib—RIPK2—endothelium—colon cancer	0.00125	0.0156	CbGeAlD
Vandetanib—PLK4—Topotecan—Irinotecan—colon cancer	0.00119	0.445	CbGdCrCtD
Vandetanib—FLT4—blood vessel—colon cancer	0.00116	0.0145	CbGeAlD
Vandetanib—RIPK2—blood vessel—colon cancer	0.00115	0.0144	CbGeAlD
Vandetanib—Afatinib—EGFR—colon cancer	0.00106	0.249	CrCbGaD
Vandetanib—TEK—endothelium—colon cancer	0.00101	0.0126	CbGeAlD
Vandetanib—ABL1—Topotecan—Irinotecan—colon cancer	0.000998	0.374	CbGdCrCtD
Vandetanib—TEK—blood vessel—colon cancer	0.000933	0.0116	CbGeAlD
Vandetanib—SRC—endothelium—colon cancer	0.000899	0.0112	CbGeAlD
Vandetanib—PTK6—renal system—colon cancer	0.000877	0.0109	CbGeAlD
Vandetanib—SRC—blood vessel—colon cancer	0.000829	0.0103	CbGeAlD
Vandetanib—KDR—endothelium—colon cancer	0.000827	0.0103	CbGeAlD
Vandetanib—BLK—lymphoid tissue—colon cancer	0.000768	0.00957	CbGeAlD
Vandetanib—KDR—blood vessel—colon cancer	0.000763	0.0095	CbGeAlD
Vandetanib—Erlotinib—EGFR—colon cancer	0.000746	0.176	CrCbGaD
Vandetanib—PTK6—digestive system—colon cancer	0.000719	0.00896	CbGeAlD
Vandetanib—BMPR1B—epithelium—colon cancer	0.000717	0.00893	CbGeAlD
Vandetanib—FLT4—embryo—colon cancer	0.000692	0.00863	CbGeAlD
Vandetanib—Bosutinib—SRC—colon cancer	0.000684	0.161	CrCbGaD
Vandetanib—PDGFRB—blood vessel—colon cancer	0.00066	0.00823	CbGeAlD
Vandetanib—ERBB3—embryo—colon cancer	0.000659	0.00821	CbGeAlD
Vandetanib—PTK6—vagina—colon cancer	0.000635	0.00792	CbGeAlD
Vandetanib—PDGFRB—gall bladder—colon cancer	0.000621	0.00774	CbGeAlD
Vandetanib—RET—embryo—colon cancer	0.000611	0.00762	CbGeAlD
Vandetanib—FGR—embryo—colon cancer	0.000611	0.00762	CbGeAlD
Vandetanib—PLK4—lymphoid tissue—colon cancer	0.0006	0.00747	CbGeAlD
Vandetanib—ORM1—gall bladder—colon cancer	0.000583	0.00726	CbGeAlD
Vandetanib—FYN—embryo—colon cancer	0.00057	0.0071	CbGeAlD
Vandetanib—FLT4—epithelium—colon cancer	0.000565	0.00704	CbGeAlD
Vandetanib—TYRO3—lymphoid tissue—colon cancer	0.000563	0.00702	CbGeAlD
Vandetanib—RIPK2—epithelium—colon cancer	0.000562	0.007	CbGeAlD
Vandetanib—LYN—lymphoid tissue—colon cancer	0.00056	0.00698	CbGeAlD
Vandetanib—TEK—embryo—colon cancer	0.000557	0.00694	CbGeAlD
Vandetanib—EPHA5—digestive system—colon cancer	0.000556	0.00693	CbGeAlD
Vandetanib—PLK4—bone marrow—colon cancer	0.000546	0.0068	CbGeAlD
Vandetanib—VEGFA—smooth muscle tissue—colon cancer	0.00054	0.00673	CbGeAlD
Vandetanib—ERBB3—epithelium—colon cancer	0.000538	0.0067	CbGeAlD
Vandetanib—FMO1—renal system—colon cancer	0.000517	0.00644	CbGeAlD
Vandetanib—ALB—gall bladder—colon cancer	0.000511	0.00637	CbGeAlD
Vandetanib—ERBB3—renal system—colon cancer	0.000499	0.00622	CbGeAlD
Vandetanib—RET—epithelium—colon cancer	0.000499	0.00621	CbGeAlD
Vandetanib—SRC—embryo—colon cancer	0.000495	0.00616	CbGeAlD
Vandetanib—EPHA5—vagina—colon cancer	0.000491	0.00612	CbGeAlD
Vandetanib—ERBB3—Vinblastine—Vincristine—colon cancer	0.00048	0.18	CbGdCrCtD
Vandetanib—FLT3—lymphoid tissue—colon cancer	0.000479	0.00597	CbGeAlD
Vandetanib—AXL—smooth muscle tissue—colon cancer	0.000479	0.00596	CbGeAlD
Vandetanib—Gefitinib—EGFR—colon cancer	0.000467	0.11	CrCbGaD
Vandetanib—RET—renal system—colon cancer	0.000463	0.00576	CbGeAlD
Vandetanib—Bosutinib—EGFR—colon cancer	0.00046	0.108	CrCbGaD
Vandetanib—KDR—embryo—colon cancer	0.000455	0.00567	CbGeAlD
Vandetanib—TEK—epithelium—colon cancer	0.000454	0.00566	CbGeAlD
Vandetanib—FYN—smooth muscle tissue—colon cancer	0.000448	0.00558	CbGeAlD
Vandetanib—MAP4K5—smooth muscle tissue—colon cancer	0.000438	0.00545	CbGeAlD
Vandetanib—TEK—smooth muscle tissue—colon cancer	0.000438	0.00545	CbGeAlD
Vandetanib—FLT3—bone marrow—colon cancer	0.000436	0.00544	CbGeAlD
Vandetanib—FLT4—lymphoid tissue—colon cancer	0.000435	0.00542	CbGeAlD
Vandetanib—BLK—lymph node—colon cancer	0.000433	0.0054	CbGeAlD
Vandetanib—FYN—renal system—colon cancer	0.000431	0.00537	CbGeAlD
Vandetanib—LTK—lymph node—colon cancer	0.000429	0.00534	CbGeAlD
Vandetanib—RIPK2—digestive system—colon cancer	0.000427	0.00533	CbGeAlD
Vandetanib—FMO1—digestive system—colon cancer	0.000424	0.00528	CbGeAlD
Vandetanib—IRAK4—lymphoid tissue—colon cancer	0.000423	0.00527	CbGeAlD
Vandetanib—TEK—renal system—colon cancer	0.000421	0.00525	CbGeAlD
Vandetanib—ERBB3—lymphoid tissue—colon cancer	0.000414	0.00516	CbGeAlD
Vandetanib—LYN—liver—colon cancer	0.000412	0.00514	CbGeAlD
Vandetanib—STK35—vagina—colon cancer	0.000409	0.0051	CbGeAlD
Vandetanib—ERBB3—digestive system—colon cancer	0.000409	0.0051	CbGeAlD
Vandetanib—YES1—smooth muscle tissue—colon cancer	0.000404	0.00504	CbGeAlD
Vandetanib—SRC—epithelium—colon cancer	0.000404	0.00503	CbGeAlD
Vandetanib—ABL2—vagina—colon cancer	0.000399	0.00497	CbGeAlD
Vandetanib—FLT4—bone marrow—colon cancer	0.000396	0.00494	CbGeAlD
Vandetanib—RIPK2—bone marrow—colon cancer	0.000394	0.00491	CbGeAlD
Vandetanib—PDGFRB—embryo—colon cancer	0.000394	0.00491	CbGeAlD
Vandetanib—VEGFA—bone marrow—colon cancer	0.000393	0.0049	CbGeAlD
Vandetanib—YES1—renal system—colon cancer	0.000389	0.00485	CbGeAlD
Vandetanib—SRC—smooth muscle tissue—colon cancer	0.000389	0.00485	CbGeAlD
Vandetanib—MKNK1—lymphoid tissue—colon cancer	0.000389	0.00485	CbGeAlD
Vandetanib—STK10—renal system—colon cancer	0.000386	0.00481	CbGeAlD
Vandetanib—IRAK4—bone marrow—colon cancer	0.000385	0.00479	CbGeAlD
Vandetanib—MKNK1—digestive system—colon cancer	0.000384	0.00479	CbGeAlD
Vandetanib—RET—lymphoid tissue—colon cancer	0.000384	0.00479	CbGeAlD
Vandetanib—FGR—lymphoid tissue—colon cancer	0.000384	0.00479	CbGeAlD
Vandetanib—AXL—lymphoid tissue—colon cancer	0.000383	0.00477	CbGeAlD
Vandetanib—FGR—digestive system—colon cancer	0.000379	0.00473	CbGeAlD
Vandetanib—RET—digestive system—colon cancer	0.000379	0.00473	CbGeAlD
Vandetanib—RIPK2—vagina—colon cancer	0.000377	0.0047	CbGeAlD
Vandetanib—VEGFA—vagina—colon cancer	0.000376	0.00469	CbGeAlD
Vandetanib—FMO1—vagina—colon cancer	0.000374	0.00467	CbGeAlD
Vandetanib—SRC—renal system—colon cancer	0.000374	0.00467	CbGeAlD
Vandetanib—KDR—epithelium—colon cancer	0.000371	0.00463	CbGeAlD
Vandetanib—IRAK4—vagina—colon cancer	0.000369	0.00459	CbGeAlD
Vandetanib—FYN—lymphoid tissue—colon cancer	0.000358	0.00446	CbGeAlD
Vandetanib—KDR—smooth muscle tissue—colon cancer	0.000358	0.00446	CbGeAlD
Vandetanib—MKNK1—bone marrow—colon cancer	0.000354	0.00441	CbGeAlD
Vandetanib—FYN—digestive system—colon cancer	0.000354	0.00441	CbGeAlD
Vandetanib—FLT3—liver—colon cancer	0.000352	0.00439	CbGeAlD
Vandetanib—ABL1—embryo—colon cancer	0.000351	0.00437	CbGeAlD
Vandetanib—MAP4K5—lymphoid tissue—colon cancer	0.00035	0.00436	CbGeAlD
Vandetanib—TEK—lymphoid tissue—colon cancer	0.00035	0.00436	CbGeAlD
Vandetanib—LCK—bone marrow—colon cancer	0.00035	0.00436	CbGeAlD
Vandetanib—FGR—bone marrow—colon cancer	0.00035	0.00436	CbGeAlD
Vandetanib—STK35—liver—colon cancer	0.000345	0.0043	CbGeAlD
Vandetanib—KDR—renal system—colon cancer	0.000344	0.00429	CbGeAlD
Vandetanib—MKNK1—vagina—colon cancer	0.000339	0.00423	CbGeAlD
Vandetanib—PLK4—lymph node—colon cancer	0.000338	0.00422	CbGeAlD
Vandetanib—ABL2—liver—colon cancer	0.000337	0.00419	CbGeAlD
Vandetanib—SLK—bone marrow—colon cancer	0.000335	0.00418	CbGeAlD
Vandetanib—LCK—vagina—colon cancer	0.000335	0.00418	CbGeAlD
Vandetanib—FGR—vagina—colon cancer	0.000335	0.00418	CbGeAlD
Vandetanib—AXL—vagina—colon cancer	0.000334	0.00416	CbGeAlD
Vandetanib—EGFR—liver—colon cancer	0.000328	0.00409	CbGeAlD
Vandetanib—FYN—bone marrow—colon cancer	0.000326	0.00406	CbGeAlD
Vandetanib—FMO3—vagina—colon cancer	0.000324	0.00403	CbGeAlD
Vandetanib—YES1—lymphoid tissue—colon cancer	0.000323	0.00403	CbGeAlD
Vandetanib—PDGFRB—epithelium—colon cancer	0.000321	0.004	CbGeAlD
Vandetanib—Afatinib—ABCB1—colon cancer	0.000321	0.0757	CrCbGaD
Vandetanib—SLK—vagina—colon cancer	0.000321	0.004	CbGeAlD
Vandetanib—STK10—lymphoid tissue—colon cancer	0.00032	0.00399	CbGeAlD
Vandetanib—FLT4—liver—colon cancer	0.00032	0.00399	CbGeAlD
Vandetanib—YES1—digestive system—colon cancer	0.000319	0.00398	CbGeAlD
Vandetanib—MAP4K5—bone marrow—colon cancer	0.000319	0.00397	CbGeAlD
Vandetanib—RIPK2—liver—colon cancer	0.000318	0.00397	CbGeAlD
Vandetanib—VEGFA—liver—colon cancer	0.000318	0.00396	CbGeAlD
Vandetanib—STK10—digestive system—colon cancer	0.000316	0.00394	CbGeAlD
Vandetanib—FMO1—liver—colon cancer	0.000316	0.00394	CbGeAlD
Vandetanib—FYN—vagina—colon cancer	0.000312	0.00389	CbGeAlD
Vandetanib—BMPR1B—lymph node—colon cancer	0.000311	0.00388	CbGeAlD
Vandetanib—IRAK4—liver—colon cancer	0.000311	0.00387	CbGeAlD
Vandetanib—SRC—lymphoid tissue—colon cancer	0.000311	0.00387	CbGeAlD
Vandetanib—PDGFRB—smooth muscle tissue—colon cancer	0.00031	0.00386	CbGeAlD
Vandetanib—SRC—digestive system—colon cancer	0.000307	0.00383	CbGeAlD
Vandetanib—MAP4K5—vagina—colon cancer	0.000305	0.0038	CbGeAlD
Vandetanib—ERBB3—liver—colon cancer	0.000305	0.0038	CbGeAlD
Vandetanib—PDGFRB—renal system—colon cancer	0.000298	0.00371	CbGeAlD
Vandetanib—YES1—bone marrow—colon cancer	0.000294	0.00367	CbGeAlD
Vandetanib—EPHB6—vagina—colon cancer	0.000292	0.00363	CbGeAlD
Vandetanib—STK10—bone marrow—colon cancer	0.000292	0.00363	CbGeAlD
Vandetanib—MKNK1—liver—colon cancer	0.000286	0.00357	CbGeAlD
Vandetanib—KDR—lymphoid tissue—colon cancer	0.000286	0.00356	CbGeAlD
Vandetanib—LCK—liver—colon cancer	0.000283	0.00352	CbGeAlD
Vandetanib—FGR—liver—colon cancer	0.000283	0.00352	CbGeAlD
Vandetanib—KDR—digestive system—colon cancer	0.000282	0.00352	CbGeAlD
Vandetanib—YES1—vagina—colon cancer	0.000282	0.00351	CbGeAlD
Vandetanib—AXL—liver—colon cancer	0.000282	0.00351	CbGeAlD
Vandetanib—STK10—vagina—colon cancer	0.000279	0.00348	CbGeAlD
Vandetanib—ABL1—smooth muscle tissue—colon cancer	0.000276	0.00344	CbGeAlD
Vandetanib—FMO3—liver—colon cancer	0.000273	0.0034	CbGeAlD
Vandetanib—SLK—liver—colon cancer	0.000271	0.00338	CbGeAlD
Vandetanib—FLT3—lymph node—colon cancer	0.00027	0.00337	CbGeAlD
Vandetanib—ABL1—renal system—colon cancer	0.000266	0.00331	CbGeAlD
Vandetanib—STK35—lymph node—colon cancer	0.000265	0.0033	CbGeAlD
Vandetanib—FYN—liver—colon cancer	0.000263	0.00328	CbGeAlD
Vandetanib—KDR—bone marrow—colon cancer	0.00026	0.00324	CbGeAlD
Vandetanib—ABL2—lymph node—colon cancer	0.000258	0.00322	CbGeAlD
Vandetanib—MAP4K5—liver—colon cancer	0.000257	0.00321	CbGeAlD
Vandetanib—TEK—liver—colon cancer	0.000257	0.00321	CbGeAlD
Vandetanib—EGFR—lymph node—colon cancer	0.000252	0.00314	CbGeAlD
Vandetanib—KDR—vagina—colon cancer	0.000249	0.00311	CbGeAlD
Vandetanib—MAP2K5—vagina—colon cancer	0.000249	0.00311	CbGeAlD
Vandetanib—PDGFRB—lymphoid tissue—colon cancer	0.000248	0.00308	CbGeAlD
Vandetanib—FLT4—lymph node—colon cancer	0.000245	0.00306	CbGeAlD
Vandetanib—PDGFRB—digestive system—colon cancer	0.000244	0.00305	CbGeAlD
Vandetanib—RIPK2—lymph node—colon cancer	0.000244	0.00304	CbGeAlD
Vandetanib—VEGFA—lymph node—colon cancer	0.000243	0.00303	CbGeAlD
Vandetanib—FMO1—lymph node—colon cancer	0.000242	0.00302	CbGeAlD
Vandetanib—IRAK4—lymph node—colon cancer	0.000238	0.00297	CbGeAlD
Vandetanib—YES1—liver—colon cancer	0.000238	0.00296	CbGeAlD
Vandetanib—STK10—liver—colon cancer	0.000236	0.00294	CbGeAlD
Vandetanib—ERBB3—lymph node—colon cancer	0.000234	0.00291	CbGeAlD
Vandetanib—SRC—liver—colon cancer	0.000229	0.00285	CbGeAlD
Vandetanib—Erlotinib—ABCB1—colon cancer	0.000227	0.0535	CrCbGaD
Vandetanib—PDGFRB—bone marrow—colon cancer	0.000225	0.00281	CbGeAlD
Vandetanib—ABL1—lymphoid tissue—colon cancer	0.000221	0.00275	CbGeAlD
Vandetanib—MKNK1—lymph node—colon cancer	0.000219	0.00273	CbGeAlD
Vandetanib—ABL1—digestive system—colon cancer	0.000218	0.00272	CbGeAlD
Vandetanib—FGR—lymph node—colon cancer	0.000217	0.0027	CbGeAlD
Vandetanib—LCK—lymph node—colon cancer	0.000217	0.0027	CbGeAlD
Vandetanib—RET—lymph node—colon cancer	0.000217	0.0027	CbGeAlD
Vandetanib—PDGFRB—vagina—colon cancer	0.000216	0.00269	CbGeAlD
Vandetanib—AXL—lymph node—colon cancer	0.000216	0.00269	CbGeAlD
Vandetanib—ORM1—bone marrow—colon cancer	0.000211	0.00263	CbGeAlD
Vandetanib—KDR—liver—colon cancer	0.00021	0.00262	CbGeAlD
Vandetanib—MAP2K5—liver—colon cancer	0.00021	0.00262	CbGeAlD
Vandetanib—FMO3—lymph node—colon cancer	0.000209	0.00261	CbGeAlD
Vandetanib—SLK—lymph node—colon cancer	0.000208	0.00259	CbGeAlD
Vandetanib—FYN—lymph node—colon cancer	0.000202	0.00252	CbGeAlD
Vandetanib—ABL1—bone marrow—colon cancer	0.000201	0.0025	CbGeAlD
Vandetanib—MAP4K5—lymph node—colon cancer	0.000197	0.00246	CbGeAlD
Vandetanib—TEK—lymph node—colon cancer	0.000197	0.00246	CbGeAlD
Vandetanib—Sinusitis—Fluorouracil—colon cancer	0.000196	0.00237	CcSEcCtD
Vandetanib—Haemorrhage—Irinotecan—colon cancer	0.000196	0.00237	CcSEcCtD
Vandetanib—Cardiac failure—Capecitabine—colon cancer	0.000194	0.00234	CcSEcCtD
Vandetanib—Lethargy—Capecitabine—colon cancer	0.000193	0.00233	CcSEcCtD
Vandetanib—ABL1—vagina—colon cancer	0.000192	0.0024	CbGeAlD
Vandetanib—Hyponatraemia—Capecitabine—colon cancer	0.00019	0.0023	CcSEcCtD
Vandetanib—Cystitis noninfective—Methotrexate—colon cancer	0.00019	0.00229	CcSEcCtD
Vandetanib—Gastrointestinal haemorrhage—Capecitabine—colon cancer	0.00019	0.00229	CcSEcCtD
Vandetanib—Visual impairment—Irinotecan—colon cancer	0.000189	0.00228	CcSEcCtD
Vandetanib—EPHB6—lymph node—colon cancer	0.000189	0.00235	CbGeAlD
Vandetanib—Haemoglobin—Fluorouracil—colon cancer	0.000189	0.00228	CcSEcCtD
Vandetanib—Cystitis—Methotrexate—colon cancer	0.000188	0.00227	CcSEcCtD
Vandetanib—Depressed level of consciousness—Methotrexate—colon cancer	0.000188	0.00227	CcSEcCtD
Vandetanib—Haemorrhage—Fluorouracil—colon cancer	0.000188	0.00227	CcSEcCtD
Vandetanib—Cardiac disorder—Vincristine—colon cancer	0.000187	0.00225	CcSEcCtD
Vandetanib—Angiopathy—Vincristine—colon cancer	0.000183	0.0022	CcSEcCtD
Vandetanib—YES1—lymph node—colon cancer	0.000182	0.00227	CbGeAlD
Vandetanib—PDGFRB—liver—colon cancer	0.000182	0.00227	CbGeAlD
Vandetanib—Cardiac disorder—Irinotecan—colon cancer	0.000182	0.00219	CcSEcCtD
Vandetanib—Mediastinal disorder—Vincristine—colon cancer	0.000181	0.00219	CcSEcCtD
Vandetanib—STK10—lymph node—colon cancer	0.000181	0.00225	CbGeAlD
Vandetanib—Cardiac arrest—Capecitabine—colon cancer	0.00018	0.00218	CcSEcCtD
Vandetanib—Alopecia—Vincristine—colon cancer	0.000178	0.00215	CcSEcCtD
Vandetanib—Angiopathy—Irinotecan—colon cancer	0.000178	0.00215	CcSEcCtD
Vandetanib—Blood creatinine increased—Capecitabine—colon cancer	0.000178	0.00214	CcSEcCtD
Vandetanib—Mediastinal disorder—Irinotecan—colon cancer	0.000177	0.00213	CcSEcCtD
Vandetanib—Dehydration—Capecitabine—colon cancer	0.000176	0.00213	CcSEcCtD
Vandetanib—Mental disorder—Vincristine—colon cancer	0.000176	0.00213	CcSEcCtD
Vandetanib—Bladder pain—Methotrexate—colon cancer	0.000176	0.00212	CcSEcCtD
Vandetanib—Neoplasm—Methotrexate—colon cancer	0.000176	0.00212	CcSEcCtD
Vandetanib—SRC—lymph node—colon cancer	0.000175	0.00219	CbGeAlD
Vandetanib—Arrhythmia—Irinotecan—colon cancer	0.000175	0.00211	CcSEcCtD
Vandetanib—Dry skin—Capecitabine—colon cancer	0.000174	0.0021	CcSEcCtD
Vandetanib—Alopecia—Irinotecan—colon cancer	0.000173	0.00209	CcSEcCtD
Vandetanib—Hypokalaemia—Capecitabine—colon cancer	0.000173	0.00208	CcSEcCtD
Vandetanib—ORM1—liver—colon cancer	0.000171	0.00213	CbGeAlD
Vandetanib—Nasopharyngitis—Capecitabine—colon cancer	0.00017	0.00205	CcSEcCtD
Vandetanib—Sepsis—Methotrexate—colon cancer	0.000169	0.00204	CcSEcCtD
Vandetanib—Gastritis—Capecitabine—colon cancer	0.000168	0.00202	CcSEcCtD
Vandetanib—Arrhythmia—Fluorouracil—colon cancer	0.000168	0.00202	CcSEcCtD
Vandetanib—Alanine aminotransferase increased—Capecitabine—colon cancer	0.000167	0.00202	CcSEcCtD
Vandetanib—Alopecia—Fluorouracil—colon cancer	0.000166	0.002	CcSEcCtD
Vandetanib—Muscle spasms—Irinotecan—colon cancer	0.000164	0.00198	CcSEcCtD
Vandetanib—Influenza—Capecitabine—colon cancer	0.000164	0.00198	CcSEcCtD
Vandetanib—Dysphagia—Capecitabine—colon cancer	0.000164	0.00198	CcSEcCtD
Vandetanib—ABL1—liver—colon cancer	0.000162	0.00202	CbGeAlD
Vandetanib—MAP2K5—lymph node—colon cancer	0.000161	0.00201	CbGeAlD
Vandetanib—KDR—lymph node—colon cancer	0.000161	0.00201	CbGeAlD
Vandetanib—Bronchospasm—Capecitabine—colon cancer	0.000161	0.00195	CcSEcCtD
Vandetanib—Bronchitis—Capecitabine—colon cancer	0.000158	0.0019	CcSEcCtD
Vandetanib—Vision blurred—Fluorouracil—colon cancer	0.000154	0.00186	CcSEcCtD
Vandetanib—Neutropenia—Capecitabine—colon cancer	0.000153	0.00185	CcSEcCtD
Vandetanib—Dysuria—Capecitabine—colon cancer	0.000153	0.00185	CcSEcCtD
Vandetanib—Upper respiratory tract infection—Capecitabine—colon cancer	0.000152	0.00184	CcSEcCtD
Vandetanib—Convulsion—Vincristine—colon cancer	0.000152	0.00183	CcSEcCtD
Vandetanib—Hypertension—Vincristine—colon cancer	0.000151	0.00183	CcSEcCtD
Vandetanib—Loss of consciousness—Irinotecan—colon cancer	0.00015	0.00181	CcSEcCtD
Vandetanib—ALB—liver—colon cancer	0.00015	0.00187	CbGeAlD
Vandetanib—Photosensitivity reaction—Capecitabine—colon cancer	0.00015	0.00181	CcSEcCtD
Vandetanib—Cough—Irinotecan—colon cancer	0.000149	0.0018	CcSEcCtD
Vandetanib—Weight decreased—Capecitabine—colon cancer	0.000148	0.00179	CcSEcCtD
Vandetanib—Hyperglycaemia—Capecitabine—colon cancer	0.000148	0.00178	CcSEcCtD
Vandetanib—Hypertension—Irinotecan—colon cancer	0.000147	0.00178	CcSEcCtD
Vandetanib—Pneumonia—Capecitabine—colon cancer	0.000147	0.00177	CcSEcCtD
Vandetanib—ABCC1—vagina—colon cancer	0.000147	0.00183	CbGeAlD
Vandetanib—Infestation NOS—Capecitabine—colon cancer	0.000146	0.00176	CcSEcCtD
Vandetanib—Infestation—Capecitabine—colon cancer	0.000146	0.00176	CcSEcCtD
Vandetanib—Depression—Capecitabine—colon cancer	0.000146	0.00176	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Capecitabine—colon cancer	0.000145	0.00175	CcSEcCtD
Vandetanib—Lethargy—Methotrexate—colon cancer	0.000144	0.00174	CcSEcCtD
Vandetanib—Renal failure—Capecitabine—colon cancer	0.000144	0.00173	CcSEcCtD
Vandetanib—Oedema—Vincristine—colon cancer	0.000143	0.00173	CcSEcCtD
Vandetanib—Stomatitis—Capecitabine—colon cancer	0.000142	0.00172	CcSEcCtD
Vandetanib—Gefitinib—ABCB1—colon cancer	0.000142	0.0335	CrCbGaD
Vandetanib—Infection—Vincristine—colon cancer	0.000142	0.00171	CcSEcCtD
Vandetanib—Urinary tract infection—Capecitabine—colon cancer	0.000142	0.00171	CcSEcCtD
Vandetanib—Conjunctivitis—Capecitabine—colon cancer	0.000142	0.00171	CcSEcCtD
Vandetanib—Convulsion—Fluorouracil—colon cancer	0.000142	0.00171	CcSEcCtD
Vandetanib—Nervous system disorder—Vincristine—colon cancer	0.00014	0.00169	CcSEcCtD
Vandetanib—Thrombocytopenia—Vincristine—colon cancer	0.00014	0.00169	CcSEcCtD
Vandetanib—Bosutinib—ABCB1—colon cancer	0.00014	0.0329	CrCbGaD
Vandetanib—PDGFRB—lymph node—colon cancer	0.00014	0.00174	CbGeAlD
Vandetanib—Haematuria—Capecitabine—colon cancer	0.000139	0.00168	CcSEcCtD
Vandetanib—Oedema—Irinotecan—colon cancer	0.000139	0.00168	CcSEcCtD
Vandetanib—Chest pain—Fluorouracil—colon cancer	0.000139	0.00168	CcSEcCtD
Vandetanib—Infection—Irinotecan—colon cancer	0.000138	0.00167	CcSEcCtD
Vandetanib—Hepatobiliary disease—Capecitabine—colon cancer	0.000138	0.00167	CcSEcCtD
Vandetanib—Epistaxis—Capecitabine—colon cancer	0.000138	0.00166	CcSEcCtD
Vandetanib—Nervous system disorder—Irinotecan—colon cancer	0.000137	0.00165	CcSEcCtD
Vandetanib—Thrombocytopenia—Irinotecan—colon cancer	0.000136	0.00165	CcSEcCtD
Vandetanib—Bradycardia—Capecitabine—colon cancer	0.000134	0.00161	CcSEcCtD
Vandetanib—Oedema—Fluorouracil—colon cancer	0.000133	0.00161	CcSEcCtD
Vandetanib—Infection—Fluorouracil—colon cancer	0.000132	0.0016	CcSEcCtD
Vandetanib—Haemoglobin—Capecitabine—colon cancer	0.000132	0.00159	CcSEcCtD
Vandetanib—Haemorrhage—Capecitabine—colon cancer	0.000131	0.00158	CcSEcCtD
Vandetanib—ORM1—lymph node—colon cancer	0.000131	0.00163	CbGeAlD
Vandetanib—Nervous system disorder—Fluorouracil—colon cancer	0.000131	0.00158	CcSEcCtD
Vandetanib—Thrombocytopenia—Fluorouracil—colon cancer	0.000131	0.00158	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Vincristine—colon cancer	0.00013	0.00157	CcSEcCtD
Vandetanib—Urinary tract disorder—Capecitabine—colon cancer	0.00013	0.00156	CcSEcCtD
Vandetanib—Insomnia—Vincristine—colon cancer	0.000129	0.00156	CcSEcCtD
Vandetanib—Urethral disorder—Capecitabine—colon cancer	0.000129	0.00155	CcSEcCtD
Vandetanib—Paraesthesia—Vincristine—colon cancer	0.000128	0.00155	CcSEcCtD
Vandetanib—ABCG2—bone marrow—colon cancer	0.000127	0.00158	CbGeAlD
Vandetanib—Visual impairment—Capecitabine—colon cancer	0.000126	0.00153	CcSEcCtD
Vandetanib—Insomnia—Irinotecan—colon cancer	0.000126	0.00152	CcSEcCtD
Vandetanib—Paraesthesia—Irinotecan—colon cancer	0.000125	0.00151	CcSEcCtD
Vandetanib—ABL1—lymph node—colon cancer	0.000124	0.00155	CbGeAlD
Vandetanib—Decreased appetite—Vincristine—colon cancer	0.000124	0.0015	CcSEcCtD
Vandetanib—Dyspnoea—Irinotecan—colon cancer	0.000124	0.0015	CcSEcCtD
Vandetanib—Erythema multiforme—Capecitabine—colon cancer	0.000124	0.0015	CcSEcCtD
Vandetanib—ABCC1—liver—colon cancer	0.000124	0.00154	CbGeAlD
Vandetanib—Gastrointestinal disorder—Vincristine—colon cancer	0.000123	0.00149	CcSEcCtD
Vandetanib—Fatigue—Vincristine—colon cancer	0.000123	0.00149	CcSEcCtD
Vandetanib—Eye disorder—Capecitabine—colon cancer	0.000123	0.00148	CcSEcCtD
Vandetanib—Dyspepsia—Irinotecan—colon cancer	0.000123	0.00148	CcSEcCtD
Vandetanib—Pain—Vincristine—colon cancer	0.000122	0.00148	CcSEcCtD
Vandetanib—Constipation—Vincristine—colon cancer	0.000122	0.00148	CcSEcCtD
Vandetanib—Cardiac disorder—Capecitabine—colon cancer	0.000122	0.00147	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.000121	0.00147	CcSEcCtD
Vandetanib—ABCG2—vagina—colon cancer	0.000121	0.00151	CbGeAlD
Vandetanib—Decreased appetite—Irinotecan—colon cancer	0.000121	0.00146	CcSEcCtD
Vandetanib—Insomnia—Fluorouracil—colon cancer	0.000121	0.00146	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Irinotecan—colon cancer	0.00012	0.00145	CcSEcCtD
Vandetanib—Fatigue—Irinotecan—colon cancer	0.00012	0.00145	CcSEcCtD
Vandetanib—Paraesthesia—Fluorouracil—colon cancer	0.00012	0.00145	CcSEcCtD
Vandetanib—Pancreatitis—Methotrexate—colon cancer	0.00012	0.00144	CcSEcCtD
Vandetanib—Constipation—Irinotecan—colon cancer	0.000119	0.00144	CcSEcCtD
Vandetanib—Pain—Irinotecan—colon cancer	0.000119	0.00144	CcSEcCtD
Vandetanib—Angiopathy—Capecitabine—colon cancer	0.000119	0.00144	CcSEcCtD
Vandetanib—Dyspnoea—Fluorouracil—colon cancer	0.000119	0.00143	CcSEcCtD
Vandetanib—Mediastinal disorder—Capecitabine—colon cancer	0.000118	0.00143	CcSEcCtD
Vandetanib—Dyspepsia—Fluorouracil—colon cancer	0.000117	0.00142	CcSEcCtD
Vandetanib—Arrhythmia—Capecitabine—colon cancer	0.000117	0.00141	CcSEcCtD
Vandetanib—Gastrointestinal pain—Vincristine—colon cancer	0.000117	0.00141	CcSEcCtD
Vandetanib—CYP3A4—renal system—colon cancer	0.000117	0.00145	CbGeAlD
Vandetanib—Decreased appetite—Fluorouracil—colon cancer	0.000116	0.0014	CcSEcCtD
Vandetanib—Alopecia—Capecitabine—colon cancer	0.000116	0.0014	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000115	0.00139	CcSEcCtD
Vandetanib—Mental disorder—Capecitabine—colon cancer	0.000115	0.00139	CcSEcCtD
Vandetanib—ALB—lymph node—colon cancer	0.000115	0.00143	CbGeAlD
Vandetanib—Malnutrition—Capecitabine—colon cancer	0.000114	0.00138	CcSEcCtD
Vandetanib—Neutropenia—Methotrexate—colon cancer	0.000114	0.00138	CcSEcCtD
Vandetanib—Dysuria—Methotrexate—colon cancer	0.000114	0.00138	CcSEcCtD
Vandetanib—Pain—Fluorouracil—colon cancer	0.000114	0.00138	CcSEcCtD
Vandetanib—Gastrointestinal pain—Irinotecan—colon cancer	0.000114	0.00137	CcSEcCtD
Vandetanib—Upper respiratory tract infection—Methotrexate—colon cancer	0.000113	0.00137	CcSEcCtD
Vandetanib—Body temperature increased—Vincristine—colon cancer	0.000113	0.00136	CcSEcCtD
Vandetanib—Abdominal pain—Vincristine—colon cancer	0.000113	0.00136	CcSEcCtD
Vandetanib—Dysgeusia—Capecitabine—colon cancer	0.000112	0.00135	CcSEcCtD
Vandetanib—Photosensitivity reaction—Methotrexate—colon cancer	0.000111	0.00134	CcSEcCtD
Vandetanib—Abdominal pain—Irinotecan—colon cancer	0.00011	0.00133	CcSEcCtD
Vandetanib—Body temperature increased—Irinotecan—colon cancer	0.00011	0.00133	CcSEcCtD
Vandetanib—Muscle spasms—Capecitabine—colon cancer	0.00011	0.00132	CcSEcCtD
Vandetanib—Pneumonia—Methotrexate—colon cancer	0.000109	0.00132	CcSEcCtD
Vandetanib—Infestation NOS—Methotrexate—colon cancer	0.000109	0.00131	CcSEcCtD
Vandetanib—Infestation—Methotrexate—colon cancer	0.000109	0.00131	CcSEcCtD
Vandetanib—Depression—Methotrexate—colon cancer	0.000108	0.00131	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Methotrexate—colon cancer	0.000108	0.0013	CcSEcCtD
Vandetanib—Vision blurred—Capecitabine—colon cancer	0.000108	0.0013	CcSEcCtD
Vandetanib—Tremor—Capecitabine—colon cancer	0.000107	0.00129	CcSEcCtD
Vandetanib—Renal failure—Methotrexate—colon cancer	0.000107	0.00129	CcSEcCtD
Vandetanib—Stomatitis—Methotrexate—colon cancer	0.000106	0.00128	CcSEcCtD
Vandetanib—Conjunctivitis—Methotrexate—colon cancer	0.000106	0.00128	CcSEcCtD
Vandetanib—Body temperature increased—Fluorouracil—colon cancer	0.000105	0.00127	CcSEcCtD
Vandetanib—Haematuria—Methotrexate—colon cancer	0.000104	0.00125	CcSEcCtD
Vandetanib—Hepatobiliary disease—Methotrexate—colon cancer	0.000103	0.00124	CcSEcCtD
Vandetanib—Epistaxis—Methotrexate—colon cancer	0.000103	0.00124	CcSEcCtD
Vandetanib—Asthenia—Vincristine—colon cancer	0.000103	0.00124	CcSEcCtD
Vandetanib—ABCG2—liver—colon cancer	0.000102	0.00128	CbGeAlD
Vandetanib—Loss of consciousness—Capecitabine—colon cancer	0.0001	0.00121	CcSEcCtD
Vandetanib—Asthenia—Irinotecan—colon cancer	9.99e-05	0.00121	CcSEcCtD
Vandetanib—Cough—Capecitabine—colon cancer	9.96e-05	0.0012	CcSEcCtD
Vandetanib—Hypertension—Capecitabine—colon cancer	9.86e-05	0.00119	CcSEcCtD
Vandetanib—Haemoglobin—Methotrexate—colon cancer	9.81e-05	0.00118	CcSEcCtD
Vandetanib—Diarrhoea—Vincristine—colon cancer	9.78e-05	0.00118	CcSEcCtD
Vandetanib—Haemorrhage—Methotrexate—colon cancer	9.76e-05	0.00118	CcSEcCtD
Vandetanib—Arthralgia—Capecitabine—colon cancer	9.72e-05	0.00117	CcSEcCtD
Vandetanib—Chest pain—Capecitabine—colon cancer	9.72e-05	0.00117	CcSEcCtD
Vandetanib—Anxiety—Capecitabine—colon cancer	9.69e-05	0.00117	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	9.65e-05	0.00117	CcSEcCtD
Vandetanib—Urinary tract disorder—Methotrexate—colon cancer	9.64e-05	0.00116	CcSEcCtD
Vandetanib—CYP3A4—digestive system—colon cancer	9.57e-05	0.00119	CbGeAlD
Vandetanib—Urethral disorder—Methotrexate—colon cancer	9.57e-05	0.00116	CcSEcCtD
Vandetanib—Diarrhoea—Irinotecan—colon cancer	9.53e-05	0.00115	CcSEcCtD
Vandetanib—Dry mouth—Capecitabine—colon cancer	9.51e-05	0.00115	CcSEcCtD
Vandetanib—ABCC1—lymph node—colon cancer	9.48e-05	0.00118	CbGeAlD
Vandetanib—Dizziness—Vincristine—colon cancer	9.45e-05	0.00114	CcSEcCtD
Vandetanib—Pruritus—Fluorouracil—colon cancer	9.43e-05	0.00114	CcSEcCtD
Vandetanib—Visual impairment—Methotrexate—colon cancer	9.41e-05	0.00114	CcSEcCtD
Vandetanib—Oedema—Capecitabine—colon cancer	9.32e-05	0.00112	CcSEcCtD
Vandetanib—Infection—Capecitabine—colon cancer	9.26e-05	0.00112	CcSEcCtD
Vandetanib—Erythema multiforme—Methotrexate—colon cancer	9.23e-05	0.00111	CcSEcCtD
Vandetanib—Dizziness—Irinotecan—colon cancer	9.21e-05	0.00111	CcSEcCtD
Vandetanib—Nervous system disorder—Capecitabine—colon cancer	9.14e-05	0.0011	CcSEcCtD
Vandetanib—Eye disorder—Methotrexate—colon cancer	9.12e-05	0.0011	CcSEcCtD
Vandetanib—Diarrhoea—Fluorouracil—colon cancer	9.12e-05	0.0011	CcSEcCtD
Vandetanib—Thrombocytopenia—Capecitabine—colon cancer	9.12e-05	0.0011	CcSEcCtD
Vandetanib—Vomiting—Vincristine—colon cancer	9.09e-05	0.0011	CcSEcCtD
Vandetanib—Cardiac disorder—Methotrexate—colon cancer	9.06e-05	0.00109	CcSEcCtD
Vandetanib—Skin disorder—Capecitabine—colon cancer	9.05e-05	0.00109	CcSEcCtD
Vandetanib—Rash—Vincristine—colon cancer	9.01e-05	0.00109	CcSEcCtD
Vandetanib—Dermatitis—Vincristine—colon cancer	9.01e-05	0.00109	CcSEcCtD
Vandetanib—Headache—Vincristine—colon cancer	8.96e-05	0.00108	CcSEcCtD
Vandetanib—Angiopathy—Methotrexate—colon cancer	8.86e-05	0.00107	CcSEcCtD
Vandetanib—Vomiting—Irinotecan—colon cancer	8.85e-05	0.00107	CcSEcCtD
Vandetanib—Dizziness—Fluorouracil—colon cancer	8.82e-05	0.00106	CcSEcCtD
Vandetanib—Mediastinal disorder—Methotrexate—colon cancer	8.8e-05	0.00106	CcSEcCtD
Vandetanib—Rash—Irinotecan—colon cancer	8.78e-05	0.00106	CcSEcCtD
Vandetanib—Dermatitis—Irinotecan—colon cancer	8.77e-05	0.00106	CcSEcCtD
Vandetanib—Headache—Irinotecan—colon cancer	8.72e-05	0.00105	CcSEcCtD
Vandetanib—Alopecia—Methotrexate—colon cancer	8.63e-05	0.00104	CcSEcCtD
Vandetanib—Mental disorder—Methotrexate—colon cancer	8.55e-05	0.00103	CcSEcCtD
Vandetanib—Malnutrition—Methotrexate—colon cancer	8.5e-05	0.00103	CcSEcCtD
Vandetanib—Nausea—Vincristine—colon cancer	8.49e-05	0.00102	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Capecitabine—colon cancer	8.49e-05	0.00102	CcSEcCtD
Vandetanib—Vomiting—Fluorouracil—colon cancer	8.48e-05	0.00102	CcSEcCtD
Vandetanib—Insomnia—Capecitabine—colon cancer	8.43e-05	0.00102	CcSEcCtD
Vandetanib—Rash—Fluorouracil—colon cancer	8.41e-05	0.00101	CcSEcCtD
Vandetanib—Dermatitis—Fluorouracil—colon cancer	8.4e-05	0.00101	CcSEcCtD
Vandetanib—Paraesthesia—Capecitabine—colon cancer	8.37e-05	0.00101	CcSEcCtD
Vandetanib—Headache—Fluorouracil—colon cancer	8.35e-05	0.00101	CcSEcCtD
Vandetanib—Dysgeusia—Methotrexate—colon cancer	8.32e-05	0.001	CcSEcCtD
Vandetanib—Dyspnoea—Capecitabine—colon cancer	8.31e-05	0.001	CcSEcCtD
Vandetanib—Nausea—Irinotecan—colon cancer	8.27e-05	0.000998	CcSEcCtD
Vandetanib—Dyspepsia—Capecitabine—colon cancer	8.2e-05	0.00099	CcSEcCtD
Vandetanib—Decreased appetite—Capecitabine—colon cancer	8.1e-05	0.000978	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Capecitabine—colon cancer	8.04e-05	0.000971	CcSEcCtD
Vandetanib—Fatigue—Capecitabine—colon cancer	8.03e-05	0.00097	CcSEcCtD
Vandetanib—Vision blurred—Methotrexate—colon cancer	8.01e-05	0.000967	CcSEcCtD
Vandetanib—Pain—Capecitabine—colon cancer	7.97e-05	0.000962	CcSEcCtD
Vandetanib—Constipation—Capecitabine—colon cancer	7.97e-05	0.000962	CcSEcCtD
Vandetanib—Nausea—Fluorouracil—colon cancer	7.92e-05	0.000956	CcSEcCtD
Vandetanib—ABCG2—lymph node—colon cancer	7.85e-05	0.000978	CbGeAlD
Vandetanib—Gastrointestinal pain—Capecitabine—colon cancer	7.62e-05	0.00092	CcSEcCtD
Vandetanib—Cough—Methotrexate—colon cancer	7.42e-05	0.000895	CcSEcCtD
Vandetanib—Body temperature increased—Capecitabine—colon cancer	7.37e-05	0.000889	CcSEcCtD
Vandetanib—Abdominal pain—Capecitabine—colon cancer	7.37e-05	0.000889	CcSEcCtD
Vandetanib—Convulsion—Methotrexate—colon cancer	7.36e-05	0.000889	CcSEcCtD
Vandetanib—Chest pain—Methotrexate—colon cancer	7.24e-05	0.000873	CcSEcCtD
Vandetanib—Arthralgia—Methotrexate—colon cancer	7.24e-05	0.000873	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	7.19e-05	0.000867	CcSEcCtD
Vandetanib—CYP3A4—liver—colon cancer	7.13e-05	0.000889	CbGeAlD
Vandetanib—Infection—Methotrexate—colon cancer	6.89e-05	0.000832	CcSEcCtD
Vandetanib—Nervous system disorder—Methotrexate—colon cancer	6.8e-05	0.000821	CcSEcCtD
Vandetanib—Thrombocytopenia—Methotrexate—colon cancer	6.79e-05	0.00082	CcSEcCtD
Vandetanib—Skin disorder—Methotrexate—colon cancer	6.74e-05	0.000813	CcSEcCtD
Vandetanib—Asthenia—Capecitabine—colon cancer	6.69e-05	0.000807	CcSEcCtD
Vandetanib—Pruritus—Capecitabine—colon cancer	6.59e-05	0.000796	CcSEcCtD
Vandetanib—Diarrhoea—Capecitabine—colon cancer	6.38e-05	0.000769	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Methotrexate—colon cancer	6.32e-05	0.000763	CcSEcCtD
Vandetanib—Insomnia—Methotrexate—colon cancer	6.27e-05	0.000757	CcSEcCtD
Vandetanib—Paraesthesia—Methotrexate—colon cancer	6.23e-05	0.000752	CcSEcCtD
Vandetanib—Dyspnoea—Methotrexate—colon cancer	6.18e-05	0.000746	CcSEcCtD
Vandetanib—Dizziness—Capecitabine—colon cancer	6.16e-05	0.000744	CcSEcCtD
Vandetanib—Dyspepsia—Methotrexate—colon cancer	6.11e-05	0.000737	CcSEcCtD
Vandetanib—Decreased appetite—Methotrexate—colon cancer	6.03e-05	0.000728	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Methotrexate—colon cancer	5.99e-05	0.000723	CcSEcCtD
Vandetanib—Fatigue—Methotrexate—colon cancer	5.98e-05	0.000722	CcSEcCtD
Vandetanib—Pain—Methotrexate—colon cancer	5.93e-05	0.000716	CcSEcCtD
Vandetanib—Vomiting—Capecitabine—colon cancer	5.92e-05	0.000715	CcSEcCtD
Vandetanib—Rash—Capecitabine—colon cancer	5.88e-05	0.000709	CcSEcCtD
Vandetanib—Dermatitis—Capecitabine—colon cancer	5.87e-05	0.000708	CcSEcCtD
Vandetanib—Headache—Capecitabine—colon cancer	5.84e-05	0.000705	CcSEcCtD
Vandetanib—Gastrointestinal pain—Methotrexate—colon cancer	5.67e-05	0.000685	CcSEcCtD
Vandetanib—Nausea—Capecitabine—colon cancer	5.53e-05	0.000668	CcSEcCtD
Vandetanib—Abdominal pain—Methotrexate—colon cancer	5.48e-05	0.000662	CcSEcCtD
Vandetanib—Body temperature increased—Methotrexate—colon cancer	5.48e-05	0.000662	CcSEcCtD
Vandetanib—Asthenia—Methotrexate—colon cancer	4.98e-05	0.000601	CcSEcCtD
Vandetanib—Pruritus—Methotrexate—colon cancer	4.91e-05	0.000592	CcSEcCtD
Vandetanib—Diarrhoea—Methotrexate—colon cancer	4.75e-05	0.000573	CcSEcCtD
Vandetanib—Dizziness—Methotrexate—colon cancer	4.59e-05	0.000554	CcSEcCtD
Vandetanib—Vomiting—Methotrexate—colon cancer	4.41e-05	0.000532	CcSEcCtD
Vandetanib—Rash—Methotrexate—colon cancer	4.37e-05	0.000528	CcSEcCtD
Vandetanib—Dermatitis—Methotrexate—colon cancer	4.37e-05	0.000527	CcSEcCtD
Vandetanib—Headache—Methotrexate—colon cancer	4.35e-05	0.000524	CcSEcCtD
Vandetanib—Nausea—Methotrexate—colon cancer	4.12e-05	0.000497	CcSEcCtD
Vandetanib—SRC—Signaling Pathways—FGFR3—colon cancer	2.52e-06	1.98e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—PTGS2—colon cancer	2.51e-06	1.97e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—KRAS—colon cancer	2.5e-06	1.97e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—KRAS—colon cancer	2.5e-06	1.96e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—EGFR—colon cancer	2.5e-06	1.96e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—TP53—colon cancer	2.49e-06	1.96e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—KRAS—colon cancer	2.49e-06	1.96e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—SRC—colon cancer	2.48e-06	1.95e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—NRAS—colon cancer	2.48e-06	1.94e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—KRAS—colon cancer	2.47e-06	1.94e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—CDKN1A—colon cancer	2.47e-06	1.94e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—KRAS—colon cancer	2.47e-06	1.94e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—MYC—colon cancer	2.46e-06	1.94e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—TGFB1—colon cancer	2.46e-06	1.93e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—BRAF—colon cancer	2.45e-06	1.93e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—EP300—colon cancer	2.44e-06	1.92e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—MYC—colon cancer	2.43e-06	1.91e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—CTNNB1—colon cancer	2.43e-06	1.91e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—TGFB1—colon cancer	2.43e-06	1.91e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—NRAS—colon cancer	2.42e-06	1.9e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—EGFR—colon cancer	2.41e-06	1.89e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—HRAS—colon cancer	2.39e-06	1.87e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—NRAS—colon cancer	2.39e-06	1.87e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—EGFR—colon cancer	2.38e-06	1.87e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—SRC—colon cancer	2.38e-06	1.87e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—CDKN1A—colon cancer	2.37e-06	1.86e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—KRAS—colon cancer	2.36e-06	1.86e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—PIK3CA—colon cancer	2.36e-06	1.85e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—EP300—colon cancer	2.35e-06	1.85e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—MYC—colon cancer	2.35e-06	1.85e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—PIK3CA—colon cancer	2.35e-06	1.85e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—TGFB1—colon cancer	2.34e-06	1.84e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—AKT1—colon cancer	2.34e-06	1.84e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—KRAS—colon cancer	2.34e-06	1.84e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—KRAS—colon cancer	2.33e-06	1.83e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—APC—colon cancer	2.31e-06	1.82e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—PIK3CA—colon cancer	2.3e-06	1.81e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—EGFR—colon cancer	2.3e-06	1.81e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—PIK3CA—colon cancer	2.3e-06	1.81e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PTGS2—colon cancer	2.3e-06	1.8e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CASP3—colon cancer	2.29e-06	1.8e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—PIK3CA—colon cancer	2.29e-06	1.8e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—SRC—colon cancer	2.29e-06	1.8e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—NRAS—colon cancer	2.29e-06	1.8e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—TP53—colon cancer	2.28e-06	1.79e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—KRAS—colon cancer	2.28e-06	1.79e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—PIK3CA—colon cancer	2.27e-06	1.79e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—PIK3CA—colon cancer	2.27e-06	1.78e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—MYC—colon cancer	2.26e-06	1.77e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—EP300—colon cancer	2.26e-06	1.77e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—TGFB1—colon cancer	2.25e-06	1.77e-05	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—AKT1—colon cancer	2.25e-06	1.77e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—KRAS—colon cancer	2.25e-06	1.77e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CASP3—colon cancer	2.24e-06	1.76e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—CTNNB1—colon cancer	2.24e-06	1.76e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CCND1—colon cancer	2.23e-06	1.75e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—TP53—colon cancer	2.22e-06	1.75e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CTNNB1—colon cancer	2.21e-06	1.74e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CASP3—colon cancer	2.21e-06	1.74e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—EGFR—colon cancer	2.21e-06	1.74e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—NRAS—colon cancer	2.2e-06	1.73e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—TP53—colon cancer	2.2e-06	1.73e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—CDKN1A—colon cancer	2.19e-06	1.72e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CCND1—colon cancer	2.18e-06	1.72e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—HRAS—colon cancer	2.18e-06	1.71e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—HRAS—colon cancer	2.17e-06	1.71e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—EGFR—colon cancer	2.17e-06	1.71e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—BRAF—colon cancer	2.17e-06	1.71e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—KRAS—colon cancer	2.17e-06	1.71e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—EP300—colon cancer	2.17e-06	1.71e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—PIK3CA—colon cancer	2.17e-06	1.7e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CTNNB1—colon cancer	2.16e-06	1.7e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CDKN1A—colon cancer	2.16e-06	1.7e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CCND1—colon cancer	2.15e-06	1.69e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—PIK3CA—colon cancer	2.15e-06	1.69e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—PIK3CA—colon cancer	2.14e-06	1.68e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—KRAS—colon cancer	2.13e-06	1.67e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CTNNB1—colon cancer	2.13e-06	1.67e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—HRAS—colon cancer	2.13e-06	1.67e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—MYC—colon cancer	2.13e-06	1.67e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—HRAS—colon cancer	2.13e-06	1.67e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—TGFB1—colon cancer	2.12e-06	1.67e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—HRAS—colon cancer	2.12e-06	1.66e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CDKN1A—colon cancer	2.11e-06	1.66e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—NRAS—colon cancer	2.11e-06	1.66e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—AKT1—colon cancer	2.11e-06	1.65e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—HRAS—colon cancer	2.1e-06	1.65e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—HRAS—colon cancer	2.1e-06	1.65e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—PIK3CA—colon cancer	2.09e-06	1.64e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—KRAS—colon cancer	2.09e-06	1.64e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—EP300—colon cancer	2.08e-06	1.64e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CDKN1A—colon cancer	2.08e-06	1.63e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—TP53—colon cancer	2.08e-06	1.63e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—PIK3CA—colon cancer	2.07e-06	1.62e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—EP300—colon cancer	2.05e-06	1.61e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—KRAS—colon cancer	2.05e-06	1.61e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—MYC—colon cancer	2.05e-06	1.61e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—TGFB1—colon cancer	2.05e-06	1.61e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—EP300—colon cancer	2.01e-06	1.58e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—HRAS—colon cancer	2.01e-06	1.58e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—EGFR—colon cancer	2.01e-06	1.58e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—TP53—colon cancer	2e-06	1.57e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—SRC—colon cancer	2e-06	1.57e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—PIK3CA—colon cancer	2e-06	1.57e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—HRAS—colon cancer	1.99e-06	1.56e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—HRAS—colon cancer	1.98e-06	1.56e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—EP300—colon cancer	1.98e-06	1.56e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—KRAS—colon cancer	1.97e-06	1.55e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.96e-06	1.54e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—PIK3CA—colon cancer	1.96e-06	1.54e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—SRC—colon cancer	1.96e-06	1.54e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—NRAS—colon cancer	1.95e-06	1.53e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—VEGFA—colon cancer	1.95e-06	1.53e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—HRAS—colon cancer	1.94e-06	1.52e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—TP53—colon cancer	1.93e-06	1.52e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—AKT1—colon cancer	1.93e-06	1.51e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—SRC—colon cancer	1.93e-06	1.51e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—EGFR—colon cancer	1.92e-06	1.51e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—NRAS—colon cancer	1.92e-06	1.51e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—AKT1—colon cancer	1.92e-06	1.51e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—PIK3CA—colon cancer	1.92e-06	1.51e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—HRAS—colon cancer	1.91e-06	1.5e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—EP300—colon cancer	1.91e-06	1.5e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CASP3—colon cancer	1.91e-06	1.5e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—VEGFA—colon cancer	1.9e-06	1.5e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—KRAS—colon cancer	1.9e-06	1.49e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—PIK3CA—colon cancer	1.89e-06	1.48e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—NRAS—colon cancer	1.88e-06	1.48e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—AKT1—colon cancer	1.88e-06	1.48e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—AKT1—colon cancer	1.88e-06	1.47e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—VEGFA—colon cancer	1.88e-06	1.47e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—AKT1—colon cancer	1.87e-06	1.47e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CCND1—colon cancer	1.86e-06	1.46e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—AKT1—colon cancer	1.86e-06	1.46e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—NRAS—colon cancer	1.85e-06	1.46e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—AKT1—colon cancer	1.85e-06	1.45e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—HRAS—colon cancer	1.85e-06	1.45e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CTNNB1—colon cancer	1.84e-06	1.45e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CASP3—colon cancer	1.84e-06	1.45e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—KRAS—colon cancer	1.82e-06	1.43e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—MYC—colon cancer	1.82e-06	1.43e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—TGFB1—colon cancer	1.81e-06	1.42e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—HRAS—colon cancer	1.81e-06	1.42e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—PIK3CA—colon cancer	1.81e-06	1.42e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PPARG—colon cancer	1.8e-06	1.42e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CDKN1A—colon cancer	1.8e-06	1.41e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CCND1—colon cancer	1.79e-06	1.41e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MYC—colon cancer	1.79e-06	1.41e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TGFB1—colon cancer	1.79e-06	1.4e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—EGFR—colon cancer	1.78e-06	1.4e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—HRAS—colon cancer	1.77e-06	1.39e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CTNNB1—colon cancer	1.77e-06	1.39e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—AKT1—colon cancer	1.77e-06	1.39e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—AKT1—colon cancer	1.76e-06	1.38e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MYC—colon cancer	1.75e-06	1.38e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—EGFR—colon cancer	1.75e-06	1.38e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—AKT1—colon cancer	1.75e-06	1.37e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TGFB1—colon cancer	1.75e-06	1.37e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—HRAS—colon cancer	1.75e-06	1.37e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—PIK3CA—colon cancer	1.74e-06	1.37e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CDKN1A—colon cancer	1.73e-06	1.36e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MYC—colon cancer	1.73e-06	1.36e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TGFB1—colon cancer	1.72e-06	1.35e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—EGFR—colon cancer	1.71e-06	1.35e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—EP300—colon cancer	1.71e-06	1.34e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—AKT1—colon cancer	1.71e-06	1.34e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—EGFR—colon cancer	1.69e-06	1.33e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—AKT1—colon cancer	1.69e-06	1.33e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—KRAS—colon cancer	1.68e-06	1.32e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—HRAS—colon cancer	1.67e-06	1.31e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—PIK3CA—colon cancer	1.67e-06	1.31e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—SRC—colon cancer	1.66e-06	1.31e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—KRAS—colon cancer	1.65e-06	1.3e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—EP300—colon cancer	1.65e-06	1.29e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—AKT1—colon cancer	1.63e-06	1.28e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CASP3—colon cancer	1.63e-06	1.28e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—VEGFA—colon cancer	1.62e-06	1.27e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—KRAS—colon cancer	1.62e-06	1.27e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—HRAS—colon cancer	1.61e-06	1.27e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—PIK3CA—colon cancer	1.61e-06	1.26e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—SRC—colon cancer	1.6e-06	1.26e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—NRAS—colon cancer	1.6e-06	1.26e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—AKT1—colon cancer	1.6e-06	1.26e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—KRAS—colon cancer	1.59e-06	1.25e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CCND1—colon cancer	1.59e-06	1.25e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CTNNB1—colon cancer	1.57e-06	1.23e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—AKT1—colon cancer	1.57e-06	1.23e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—VEGFA—colon cancer	1.56e-06	1.23e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—HRAS—colon cancer	1.54e-06	1.21e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—NRAS—colon cancer	1.54e-06	1.21e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—PIK3CA—colon cancer	1.54e-06	1.21e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—AKT1—colon cancer	1.54e-06	1.21e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CDKN1A—colon cancer	1.53e-06	1.2e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—PIK3CA—colon cancer	1.52e-06	1.19e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MYC—colon cancer	1.49e-06	1.17e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—PIK3CA—colon cancer	1.49e-06	1.17e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TGFB1—colon cancer	1.49e-06	1.17e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—AKT1—colon cancer	1.48e-06	1.16e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TP53—colon cancer	1.47e-06	1.15e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—PIK3CA—colon cancer	1.46e-06	1.15e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—EP300—colon cancer	1.46e-06	1.15e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TP53—colon cancer	1.44e-06	1.13e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MYC—colon cancer	1.44e-06	1.13e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TGFB1—colon cancer	1.43e-06	1.13e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—HRAS—colon cancer	1.43e-06	1.12e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—AKT1—colon cancer	1.42e-06	1.12e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PTGS2—colon cancer	1.42e-06	1.11e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TP53—colon cancer	1.42e-06	1.11e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PIK3CA—colon cancer	1.41e-06	1.11e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—HRAS—colon cancer	1.41e-06	1.1e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—EGFR—colon cancer	1.41e-06	1.1e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ABCB1—colon cancer	1.4e-06	1.1e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—VEGFA—colon cancer	1.38e-06	1.09e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—KRAS—colon cancer	1.38e-06	1.08e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—HRAS—colon cancer	1.38e-06	1.08e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—TYMS—colon cancer	1.37e-06	1.08e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—NRAS—colon cancer	1.37e-06	1.07e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—AKT1—colon cancer	1.36e-06	1.07e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—HRAS—colon cancer	1.36e-06	1.06e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—KRAS—colon cancer	1.33e-06	1.04e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—AKT1—colon cancer	1.31e-06	1.03e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MYC—colon cancer	1.27e-06	9.99e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TGFB1—colon cancer	1.27e-06	9.97e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PIK3CA—colon cancer	1.27e-06	9.94e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—AKT1—colon cancer	1.26e-06	9.89e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—EGFR—colon cancer	1.24e-06	9.77e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—AKT1—colon cancer	1.24e-06	9.75e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TP53—colon cancer	1.22e-06	9.62e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PIK3CA—colon cancer	1.22e-06	9.58e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—AKT1—colon cancer	1.22e-06	9.55e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—AKT1—colon cancer	1.2e-06	9.4e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TP53—colon cancer	1.18e-06	9.27e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—EP300—colon cancer	1.18e-06	9.26e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—KRAS—colon cancer	1.18e-06	9.23e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—HRAS—colon cancer	1.17e-06	9.2e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—AKT1—colon cancer	1.15e-06	9.07e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—HRAS—colon cancer	1.13e-06	8.86e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PIK3CA—colon cancer	1.08e-06	8.48e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TP53—colon cancer	1.04e-06	8.2e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—AKT1—colon cancer	1.03e-06	8.12e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—HRAS—colon cancer	9.99e-07	7.85e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—AKT1—colon cancer	9.96e-07	7.83e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PPARG—colon cancer	9.72e-07	7.64e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—AKT1—colon cancer	8.82e-07	6.93e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PIK3CA—colon cancer	8.72e-07	6.85e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PTGS2—colon cancer	7.65e-07	6.01e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—AKT1—colon cancer	7.12e-07	5.59e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—EP300—colon cancer	6.36e-07	5e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PIK3CA—colon cancer	4.71e-07	3.7e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—AKT1—colon cancer	3.84e-07	3.02e-06	CbGpPWpGaD
